The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Trending
- Teenager accused of carrying out sabotage actions in Poland for Russia
- Nvidia-backed Fireworks hits $17.5 billion valuation as companies pursue cheaper AI models
- Hawaii’s most exclusive airport lounge is back, with ‘surprise and delight’ access for some flyers
- Sapphire Preferred 100,000-point bonus offer is ending soon, Chase confirms
- Patrick Mahomes shares honest reaction to falling behind Josh Allen in QB rankings
- Browns’ Jared Verse reveals ‘welcome to NFL moment,’ discusses replacing Myles Garrett
- Browns insider addresses repeated narrative about Shedeur Sanders, Deshaun Watson competition
- Which teams will unexpectedly sell at the Trade Deadline?
